FCM
FOLD

Flinton Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Flinton Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$16K Buy
+2,040
New +$22.1K ﹤0.01% 871

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Flinton Capital Management's FOLD Position: Q3 2019 in Review

Flinton Capital Management opened a new position in Amicus Therapeutics (FOLD) in Q3 2019: 2,040 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #871 among its holdings.

204 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Flinton Capital Management held 2,040 shares of Amicus Therapeutics worth $16K as of Q3 2019.
  • Amicus Therapeutics was a new Flinton Capital Management position in Q3 2019.
  • Amicus Therapeutics made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #871 holding.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.